Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
ВИЧ-инфекция у детей

Список литературы

  1. Санитарные правила СП 3.1.5.2826-10 “Профилактика ВИЧ-инфекции”, утвержденные 11 января 2011 года, с изменениями №1 от 21 июля 2016 года.
  2. Годовая форма федерального государственного статистического наблюдения № 61 «Сведения о контингентах, больных ВИЧ-инфекцией».
  3. Покровский В.В., Ладная Н.Н., Соколова Е.В., Буравцова Е.В. ВИЧ-инфекция. Информационный бюллетень №43. – М: 2018, - 55с.
  4. Ладная Н.Н., Покровский В.В., Дементьева Л.А., Соколова Е.В., Козырина Н.В., Нарсия Р.С. ВИЧ-инфекция в Российской Федерации в 2018г. Международная научно-практическая конференция «Актуальные вопросы ВИЧ-инфекции»: Материалы конференции. – СПб: Человек и .
  5. Латышева И.Б., Воронин Е.Е. ВИЧ-инфекция у детей в Российской Федерации. Международная научно-практическая конференция «Актуальные вопросы ВИЧ-инфекции. Охрана здоровья детей с ВИЧ-инфекцией в рамках реализации программы «Десятилетие детства в России». Ма.
  6. Приказ Министерства здравоохранения Российской Федерации от 16 сентября 2003г № 442 «Об утверждении учетных форм для регистрации детей, рожденных ВИЧ- инфицированными матерями».
  7. Форма № 311/у «Донесение о подтверждении диагноза у ребенка, рожденного ВИЧ- инфицированной матерью». Приложение № 5 к приказу Минздрава России от 16.09.03. №442 «Об утверждении учетных форм для регистрации детей, рожденных ВИЧ- инфицированными матерями».
  8. Приказ Министерства здравоохранения Российской федерации № 170 от 27 мая 1997 года «О переходе органов и учреждений здравоохранения Российской Федерации на Международную статистическую классификацию болезней и проблем, связанных со здоровьем X пересмотра».
  9. Овчаров В. К., Максимова М. В. (ред.). Международная статистическая классификация болезней и проблем, связанных со здоровьем: МКБ-10. – Медицина, 1995.
  10. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова В.В., Деулина М.О., Ермак Т.Н., Ефремова О.С., Канестри В.Г., Козырина Н.В., Ладная Н.Н., Нарсия Р.С., Шахгильдян В.И., Куимова У.А., Покровская А.В., Попова А.А., Хохлова О.Н., Воронин Е.
  11. Клиническая классификация ВИЧ-инфекции. Приложение к Инструкции по заполнению годовой формы государственного федерального статистического наблюдения N61 “Сведения о контингентах больных ВИЧ-инфекцией”, утвержденной Приказом Минздравсоцразвития России от .
  12. ВИЧ-инфекция и СПИД: Национальное руководство/ под ред. акад. В.В.Покровского. - М.: ГЭОТАР-Медиа, 2013. -608с.
  13. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age; Official authorized addenda: human immunodeficiency virus infection codes and official guideli.
  14. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. WHO, Geneva, 2007.
  15. Selik R.M., Mokotoff E.D., Branson B., Owen S.M., Whitmore S., Hall H.I. Revised Surveillance Case Definition for HIV Infection — United States, 2014. MMWR 2014; 63 (RR No. 3) April 11, 2014; 1-13.
  16. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, 2019. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf.
  17. The European Collaborative Study. Age-related standards for T-lymphocyte subsets based on uninfected children born to human immunodeficiency virus-1-infected women. Pediatr Infect Dis J 1992; 11:1018–26.
  18. Hecht F.M., Busch M.P., Rawal B., Rosenberg E., Swanson M., Chesney M., Anderson J., Levy J., Kahn J.O. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16(8):1119-29.
  19. Воронин Е.Е., Афонина Л.Ю., Фомин Ю.А. Антиретровирусная терапия у детей. Учебное пособие для врачей/ под ред. акад. Ю.В.Лобзина. -М.: ООО «Бионика Медиа». - 2014. - 31с.
  20. Справка «ВИЧ-инфекция в Российской Федерации в 2018 году», Федеральный научно- методический центр по профилактике и борьбе со СПИДом ФБУН ЦНИИЭ Роспотребнадзора.
  21. Tovo P. A. et al. Prognostic factors and survival in children with perinatal HIV-1 infection //The Lancet. – 1992. – Т. 339. – №. 8804. – С. 1249-1253.
  22. Махмудова Р. У., Закирова К. А. РАСПРОСТРАНЕННОСТЬ ОППОРТУНИСТИЧЕСКИХ ИНФЕКЦИЙ-ТУБЕРКУЛЕЗА, СОЧЕТАННОГО С ВИЧ-ИНФЕКЦИЕЙ, СРЕДИ ДЕТЕЙ И ПРОБЛЕМЫ РАННЕГО ВЫЯВЛЕНИЯ //Научно-практический журнал ТИППМК. – 2014. – №. 4. – С. 72-73.
  23. Садовникова В. Н. Заболеваемость и распространенность ВИЧ-инфекции среди женщин и детей //Инфекционные болезни. – 2009. – Т. 7. – №. 3. – С. 12-17.
  24. Воронин Е.Е., Афонина Л.Ю., Байбарина Е.Н., Чумакова О.В., Садовникова В.Н. Раннее выявление ВИЧ-инфекции у детей. Методические рекомендации. -2018. М: МЗ РФ. -11 с.
  25. Афонина Л.Ю., Воронин Е.Е. Совершенствование ранней диагностики ВИЧ-инфекции у детей. Международная научно-практическая конференция «Актуальные вопросы ВИЧ- инфекции. Охрана здоровья детей с ВИЧ-инфекцией в рамках реализации программы «Десятилетие детства .
  26. GogaAE. Impact of breastfeeding, maternal antiretroviral treatment and health service factors on 18-month vertical transmission of HIV and HIV-free survival: results from a nationally representative HIV-exposed infant cohort, South Africa //J Ep // J. Epidemiol. Community Health.
  27. Ngbapai J. G., Izudi J., Okoboi S. Cessation of breastfeeding and associated factors in the era of elimination of mother to child transmission of HIV at Ndejje health center, Uganda: a retrospective cohort study //International Breastfeeding Journal. – 20.
  28. Tess B. H. et al. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil //Aids. – 1998. – Т. 12. – №. 5. – С. 513-520.
  29. Pizzo P. A. et al. Markers and determinants of disease progression in children with HIV infection //The Pediatric AIDS Siena Workshop. – 1995. – Т. 8. – №. 1. – С. 30-44.
  30. Pahwa S. Human immunodeficiency virus infection in children: nature of immunodeficiency, clinical spectrum and management //The Pediatric infectious disease journal. – 1988. – Т. 7. – №. 5 Suppl. – С. S61-71.
  31. Barnhart H. X. et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project //Pediatrics. – 1996. – Т. 97. – №. 5. – С. 710-716.
  32. Cooper E. R. et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection //The Journal of pediatrics. – 1998. – Т. 132. – №. 5. – С. 808-812.
  33. Clemens, S. L., Macneal, K. D., Alons, C. L., & Cohn, J. E. (2020). Screening Algorithms to Reduce Burden of Pediatric HIV Testing. Pediatric Infectious Disease Journal, Publish Ahead of Print. doi:10.1097/inf.0000000000002715.
  34. Calis J. C. J. et al. HIV-associated anemia in children: a systematic review from a global perspective //Aids. – 2008. – Т. 22. – №. 10. – С. 1099-1112.
  35. Ziegler J. L., Katongole‐Mbidde E. Kaposi’s sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection //International Journal of Cancer. – 1996. – Т. 65. – №. 2. – С. 200-203.
  36. Granovsky M. O. et al. Cancer in human immunodeficiency virus-infected children: a case series from the Children’s Cancer Group and the National Cancer Institute //Journal of clinical oncology. – 1998. – Т. 16. – №. 5. – С. 1729-1735.
  37. Mueller B. U. Cancers in human immunodeficiency virus-infected children //JNCI Monographs. – 1998. – Т. 1998. – №. 23. – С. 31-35.
  38. B-Lajoie M. R. et al. Incidence and prevalence of opportunistic and other infections and the impact of antiretroviral therapy among HIV-infected children in low-and middle-income countries: a systematic review and meta-analysis //Clinical Infectious Disea.
  39. Diaconu I. A. et al. Diagnosing HIV-associated cerebral diseases-The importance of neuropathology in understanding HIV //Rom J Morphol Embryol. – 2016. – Т. 57. – №. 2 Suppl. – С. 745-50.
  40. Mikol J. et al. The epidemiology of cerebral lymphoma in AIDS //Journal of Neuroradiology= Journal de Neuroradiologie. – 1995. – Т. 22. – №. 3. – С. 204-206.
  41. Chitsike I. et al. Childhood cancers in Zimbabwe: a 10 year review of the Zimbabwe National cancer registry data //Central African Journal of Medicine. – 2014. – Т. 60. – №. 1. – С. 1-8..
  42. Marx, Jean L. "Human T-Cell Leukemia Virus Linked to AIDS.- Science. (May 20, 1983): 20, (4599) 806-809.
  43. Hesseling A. C. et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies //Clinical Infectious Diseases. – 2009. – Т. 48. – №. 1.
  44. Palme I. B. et al. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis //The Pediatric infectious disease journal. – 2002. – Т. 21. – №. 11. – С. 1.
  45. Dodd P. J. et al. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis //Thorax. – 2017. – Т. 72. – №. 6. – С. 559-575.
  46. Chandwani S. et al. Cytomegalovirus infection in human immunodeficiency virus type 1- infected children //The Pediatric infectious disease journal. – 1996. – Т. 15. – №. 4. – С. 310-314.
  47. Weinberg A. et al. Immune correlates of herpes zoster in HIV-infected children and youth //Journal of virology. – 2012. – Т. 86. – №. 5. – С. 2878-2881.
  48. Brandt C. D. et al. Epstein-Barr virus DNA in the blood of infants, young children, and adults by age and HIV status //Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Associa.
  49. Pollock B. H. et al. Risk factors for pediatric human immunodeficiency virus–related malignancy //Jama. – 2003. – Т. 289. – №. 18. – С. 2393-2399.
  50. Gona P. et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era //Jama. – 2006. – Т. 296. – №. 3. – С. 292-300.
  51. Brennan A. T. et al. A meta-analysis assessing diarrhea and pneumonia in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children //JAIDS Journal of Acquired Immune Deficiency Syndromes. – 2019. – Т. 82. – №. 1. – С. 1-8.
  52. Likasitwattanakul S., Poneprasert B., Sirisanthana V. Cryptococcosis in HIV-infected children //Headache. – 2004. – Т. 13. – №. 16. – С. 81.
  53. Makni F., Cheikrouhou F., Ayadi A. Parasitoses and immunodepression //Archives de l’Institut Pasteur de Tunis. – 2000. – Т. 77. – №. 1-4. – С. 51-54.
  54. Arango M. et al. Histoplasmosis: results of the Colombian national survey, 1992-2008 //Biomedica. – 2011. – Т. 31. – №. 3. – С. 344-356.
  55. Wilmshurst J. M. et al. Specific neurologic complications of human immunodeficiency virus type 1 (HIV-1) infection in children //Journal of child neurology. – 2006. – Т. 21. – №. 9. – С. 788- 794.
  56. Korir A. et al. Developing clinical strength-of-evidence approach to define HIV-associated malignancies for cancer registration in Kenya //PLoS One. – 2014. – Т. 9. – №. 1. – С. e85881.
  57. Harris, C., Mills, R., Seager, E., Blackstock, S., Hiwa, T., Pumphrey, J., … Kennedy, N. (2018). Paediatric deaths in a tertiary government hospital setting, Malawi. Paediatrics and International Child Health, 1–9. doi:10.1080/20469047.2018.1536873.
  58. Sabbagh P. et al. The global and regional prevalence, burden, and risk factors for methicillin- resistant Staphylococcus aureus colonization in HIV-infected people: a systematic review and meta-analysis //American Journal of Infection Control. – 2019. – Т.
  59. Huson M. A. M. et al. Community-acquired bacterial bloodstream infections in HIV-infected patients: a systematic review //Clinical infectious diseases. – 2014. – Т. 58. – №. 1. – С. 79-92.
  60. Oldham S. A. et al. HIV-associated lymphocytic interstitial pneumonia: radiologic manifestations and pathologic correlation //Radiology. – 1989. – Т. 170. – №. 1. – С. 83-87.
  61. Sharland M., Gibb D. M., Holland F. Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection //Archives of disease in childhood. – 1997. – Т. 76. – №. 4. – С. 334-336.
  62. Ford N. et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis //The lancet HIV. – 2015. – Т. 2. – №. 10. – С. e438-e444.
  63. Sonego M. et al. Risk factors for mortality from acute lower respiratory infections (ALRI) in children under five years of age in low and middle-income countries: a systematic review and meta-analysis of observational studies //PloS one. – 2015. – Т. 10. .
  64. Becquet R. et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis //PloS one. – 2012. – Т. 7. – №. 2. – С. e28510.
  65. Read J. S. et al. Diagnosis of HIV-1 infection in children younger than 18 months in the United States //Pediatrics. – 2007. – Т. 120. – №. 6. – С. e1547-e1562.
  66. Cohn, J., Whitehouse, K., Tuttle, J., Lueck, K., & Tran, T. (2016). Paediatric HIV testing beyond the context of prevention of mother-to-child transmission: a systematic review and meta- analysis. The Lancet HIV, 3(10), e473–e481. doi:10.1016/s2352-3018(16.
  67. Bispo S. et al. Postnatal HIV transmission in breastfed infants of HIV‐infected women on ART: a systematic review and meta‐analysis //Journal of the International AIDS Society. – 2017. – Т. 20. – №. 1. – С. 21251.
  68. Leroy V. et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection //The Lancet. – 1998. – Т. 352. – №. 9128. – С. 597-600.
  69. Schmid, J., & Chiba, J. (2017). The intersection of abandonment, HIV-positive status and residential care for a group of perinatally infected adolescents. African Journal of AIDS Research, 16(1), 47–56. doi:10.2989/16085906.2017.1296476.
  70. Read J. S. et al. Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis //The Pediatric infectious disease journal. – 2000. – Т. 19. – №. 6. – С. 54.
  71. Claassen M. et al. Pitfalls with rapid HIV antibody testing in HIV-infected children in the Western Cape, South Africa //Journal of clinical virology. – 2006. – Т. 37. – №. 1. – С. 68-71.
  72. Urassa W. et al. Evaluation of the WHO human immunodeficiency virus (HIV) antibody testing strategy for the diagnosis of HIV infection //Clinical and diagnostic virology. – 1994. – Т. 2. – №. 1. – С. 1-6.
  73. Nielsen K., Bryson Y. J. Diagnosis of HIV infection in children //Pediatric Clinics of North America. – 2000. – Т. 47. – №. 1. – С. 39-63.
  74. Burgard M. et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis //The Journal of pediatrics. – 2012. – Т. 160. – №. 1. – С. 60-66. e1.
  75. Rouet F. et al. Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay //Aids. – 2001. – Т. 15. – № . 14. – С. 1849- 1856.
  76. Weintrub P. S. et al. Use of polymerase chain reaction for the early detection of HIV infection in the infants of HIV-seropositive women //AIDS (London, England). – 1991. – Т. 5. – № . 7. – С. 881-884.
  77. Updated recommendations on first-line and second-line antiretroviral regimens and post- exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.18). License: CC BY.
  78. Gulia J., Kumwenda N., Li Q., Taha T.E. HIV seroreversion time in HIV-1-uninfected children born to HIV-1-infected mothers in Malawi. J Acquir Immune Defic Syndr. 2007;46(3):332-337.
  79. Alcantara K.C., Pereira G.A., Albuquerque M., Stefani M.M. Seroreversion in children born to HIV-positive and AIDS mothers from Central West Brazil. Trans R Soc Trop Med Hyg. 2009;103(6):620-626.
  80. 1. Sohn A.H., Thanh T.C., Thinh le Q., et al. Failure of human immunodeficiency virus enzyme immunoassay to rule out infection among polymerase chain reaction-negative Vietnamese infants at 12 months of age. Pediatr Infect Dis J.2009;28(4):273-276.
  81. Bamford A., Turkova A., Lyall H., Foster C., Klein N., Bastiaans D., Burger D., Bernadi S., Butler K., Chiappini E., Clayden P., Della Negra M., Giacomet V., Giaquinto C., Gibb D., Galli L., Hainaut M., Koros M., Marques L., Nastouli E., Niehues T., Nogue.
  82. Rogers M.F., Ou C.Y., Rayfield M., et al. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. New York City Collaborative Study of Maternal HIV Transmi.
  83. Fiscus S.A., McMillion T., Nelson J.A., Miller W.C. Validation of the gen-probe aptima qualitative HIV-1 RNA assay for diagnosis of human immunodeficiency virus infection in infants. J Clin Microbiol. 2013;51(12):4137-4140.
  84. Technau K.G., Mazanderani A.H., Kuhn l., et al. Prevalence and outcomes of HIV-1 diagnostic challenges during universal birth testing – an Sous African observational cohort. J Int AIDS Soc. 2017; 20 (Suppl 6): 217-61.
  85. Jendis J.B., Tomasik Z., Hunziker Jourdain Jourdain U., et al. Evaluation of diagnostic tests for HIV infection in infants born to HIV-infected mothers in Switzerland. AIDS. 1988;2(4):273-9.
  86. Donovan M., Palumbo P. Diagnosis of HIV: challenges and strategies for HIV prevention and detection among pregnant women and their infants. Clin Perinatol. 2010;37(4):751-763, viii.
  87. Luzuriaga K., Sullivan J.L. DNA polymerase chain reaction for the diagnosis of vertical HIV infection. JAMA.1996;275 (17):1360– 1361.
  88. Read J.S., Committee on Pediatric AIDS, American Academy of Pediatrics. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics. 2007;120(6): e1547- 1562.
  89. Arikawa S. et al. Mortality risk and associated factors in HIV‐exposed, uninfected children //Tropical Medicine & International Health. – 2016. – Т. 21. – №. 6. – С. 720-734.
  90. Veloso V. G. et al. HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil //Revista de saude publica. – 2010. – Т. 44. – №. 5. – С. 803-811.
  91. Cassol S. et al. Rapid screening for early detection of mother-to-child transmission of human immunodeficiency virus type 1 //Journal of clinical microbiology. – 1994. – Т. 32. – №. 11. – С. 2641-2645.
  92. Mallampati D. et al. Performance of virological testing for early infant diagnosis: a systematic review //JAIDS Journal of Acquired Immune Deficiency Syndromes. – 2017. – Т. 75. – №. 3. – С. 308-314.
  93. Brown E. et al. Determining an optimal testing strategy for infants at risk for mother-to- child transmission of HIV-1 during the late postnatal period //AIDS (London, England). – 2008. – Т. 22. – №. 17. – С. 2341.
  94. Frange P. et al. Late postnatal HIV infection in children born to HIV-1-infected mothers in a high-income country //Aids. – 2010. – Т. 24. – №. 11. – С. 1771-1776.
  95. Coutsoudis A. et al. Breastfeeding and IIV International Transmission Study Group: Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis //J Infect Dis. – 2004. – Т. 189. – №. 12. – С. 2154-2166.
  96. World Health Organization et al. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guid.
  97. Gibb D. M. et al. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis //AIDS (London, England). – 2008. – Т. 22. – С. 97-105.
  98. Mugglin C. et al. Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: systematic review //PLoS One. – 2013. – Т. 8. – №. 2. – С. e56446.
  99. Study H. I. V. P. P. M. C. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data //The Lancet. – 2005. – Т. 366. – №. 9500. – С. 1868-1874.
  100. Hughes R.A., May M.T., Tilling K., Taylor N., Wittkop L., Rei P., Gill J., Schommers P., Costagliola D., Guest J.L., Lima V.D., Monforte A.d’A., Smith C., Cavassini M., Saag M., Castilho J.L., Sterne J.A.C. Long terms trends in CD4+ cell counts, CD8+ cell.
  101. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. 2019.
  102. O’Gorman M. R. G., Zijenah L. S. CD4 T cell measurements in the management of antiretroviral therapy—A review with an emphasis on pediatric HIV‐infected patients //Cytometry Part B: Clinical Cytometry: The Journal of the International Society for Analytic.
  103. Guillén S. et al. Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children //PloS one. – 2019. – Т. 14. – №. 8. – С. e0220552.
  104. Ray K., Gupta S.M., Bala M., Muralidhar S., Kumar J. CD4/CD8 lymphocyte counts in healthy, HIV-positive individuals & AIDS patients. - Indian J Med Res 124, September 2006, pp 319-330.
  105. Trickey A., May M.T., Schommers P., et al. CD4:CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the Antiretroviral Therapy Cohort Collaboration (ART-CC). Clin Infect D.
  106. Mussini C., Lorenzini P., Cozzi-Lepri A., et al. CD4/CD8 ratio normalization and non-AIDS related events in individuals with HIV who achieved viral load suppression on antiretroviral therapy: an observational cohort study. Lancet HIV. 2015;2: e98–106.
  107. Serrano-Villar S., Saiz T., Sulggi A.L., et al. HIV infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+T cell activation and increased risk of non-AIDS morbidity and mortalit.
  108. Serrano-Villar S., Moreno S., Fuentes-Ferrer M. et al. The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med. 2014; 15: 40-49.
  109. Hema M.N., Ferry T., Dupon M., et al. Low CD4/CD8 ratio is associated with non-AIDS- defining cancers in patients on antiretroviral therapy: ANRS CO8(Aproco/copilote) prospective cohort study. PLoS One. 2016;11:e0161594.
  110. Triplette M., Attia E.F., Akgun K.M., et al. A low peripheral blood CD4/CD8 ratio is associated with pulmonary emphysema in HIV. PLoS One. 2017;12:e0170857.
  111. Chereau F., Madec Y., Sabin C., Obel N., Ruiz-Mateos E., Chrysos G., Fidler S., Lehmann C., Zangerle Robert., Wittkop L., Reiss P., Hamouda O., Estrada Perez V., The HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemio.
  112. Gibellini L.; Pecorini S.; De Biasi S.; Bianchini E.; Digaetano M.; Pinti M.; Carnevale G.; Borghi V.; Guaraldi G.; Mussini C.; Cossarizza A.; Nasi M. HIV-DNA content in different CD4+T-cell subsets correlates with CD4+cell : CD8+ cell ratio or length of .
  113. Mofenson L. M. et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1—infected children //Journal of Infectious Diseases. – 1997. – Т. 175. – №. 5. – С. 10.
  114. Adetifa I. M. O. et al. Haematological abnormalities associated with paediatric HIV/AIDS in Lagos //Annals of tropical paediatrics. – 2006. – Т. 26. – №. 2. – С. 121-125.
  115. Ruhinda E. N., Bajunirwe F., Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART //BMC pediatrics. – 2012. – Т. 12. – №. 1. – С. 1-6.
  116. Strehlau R. et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy //Journal of acquired immune deficiency syndromes (1999). – 2012. – Т. 60. – №. 4. – С. 369.
  117. Manglani M. V. et al. HLA-B* 5701 allele in HIV-infected Indian children and its association with Abacavir hypersensitivity //Indian pediatrics. – 2018. – Т. 55. – №. 2. – С. 140-141.
  118. Puthanakit T. et al. Prevalence of human leukocyte antigen-B* 5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use //The Pediatric infectious disease journal. – 2013. – Т. 32. – №. 3. – С. 252.
  119. Jesson J. et al. Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis //The Lancet HIV. – 2016. – Т. 3. – №. 2. – С. e64-e75.
  120. Cargnin, S., Jommi, C., Canonico, P. L., Genazzani, A. A., & Terrazzino, S. (2014). Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. Pharmacogenomics, 15.
  121. Hammond E. et al. External quality assessment of HLA-B* 5701 reporting: an international multicentre survey //Antiviral therapy. – 2007. – Т. 12. – №. 7. – С. 1027-1032.
  122. Esezobor C. I. et al. Prevalence of proteinuria among HIV-infected children attending a tertiary hospital in Lagos, Nigeria //Journal of tropical pediatrics. – 2010. – Т. 56. – №. 3. – С. 187- 190.
  123. Eke F. U. et al. Microalbuminuria in children with human immunodeficiency virus (HIV) infection in Port Harcourt, Nigeria //Nigerian Journal of Medicine. – 2010. – Т. 19. – №. 3.
  124. Telatela S. P., Matee M. I., Munubhi E. K. Seroprevalence of hepatitis B and C viral co- infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Sa.
  125. Campos F. A. et al. Incidence of congenital toxoplasmosis among infants born to HIV- coinfected mothers: case series and literature review //Brazilian Journal of Infectious Diseases. – 2014. – Т. 18. – №. 6. – С. 609-617.
  126. Suri D. et al. Cytomegalovirus Disease in HIV-infected Children—A Single-Centre Clinical Experience over 23 Years //Journal of Tropical Pediatrics. – 2018. – Т. 64. – №. 3. – С. 215-224.
  127. Aggerbeck H. et al. C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial //PloS one. – 2018. – Т. 13. – №. 9. – С. e0204554.
  128. Ford, N., Shubber, Z., Meintjes, G., Grinsztejn, B., Eholie, S., Mills, E. J., … Doherty, M. (2015). Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. The Lancet HIV, 2(10), e438–e444. doi:10.1016/.
  129. Gonzalez C. E. et al. Cryptococcosis in human immunodeficiency virus-infected children //The Pediatric infectious disease journal. – 1996. – Т. 15. – №. 9. – С. 796-800.
  130. Marcy O. et al. Performance of Xpert MTB/RIF and alternative specimen collection methods for the diagnosis of tuberculosis in HIV-infected children //Clinical Infectious Diseases. – 2016. – Т. 62. – №. 9. – С. 1161-1168.
  131. Mendez H. Ambulatory care of HIV-seropositive infants and children //The Journal of pediatrics. – 1991. – Т. 119. – №. 1. – С. S14-S17.
  132. StudyM H. I. V. P. P. M. C. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children //Aids. – 2006. – Т. 20. – №. 9. – С. 1289-1294.
  133. Tetali S. et al. Virus load as a marker of disease progression in HIV-infected children //AIDS research and human retroviruses. – 1996. – Т. 12. – №. 8. – С. 669-675.
  134. KalishLA. Evaluation of Human Immunodeficiency Virus (HIV) Type 1 Load, CD4 T Cell Level, and Clinical Class as Time-Fixed and Time-Varying Markers of Disease Progression in HIV-1 —Infected Children // J. Infect. Dis. 1999. Vol. 180, № 5. P. 1514–1520.
  135. Palumbo P. E. et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children //Jama. – 1998. – Т. 279. – №. 10. – С. 756-761.
  136. ARROW Trial Team et al. Routine versus clinically driven laboratory monitoring and first- line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial //The Lancet. – 2013. – Т. 381. – №. 9875.
  137. Leão F. V. F. et al. Renal abnormalities in a cohort of HIV-infected children and adolescents //Pediatric Nephrology. – 2016. – Т. 31. – №. 5. – С. 773-778.
  138. Adetokunboh O. O. et al. The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis //Human Vaccines & Immunotherapeutics. – 2019. – Т. 15. – №. 11. – С. 2590-2605.
  139. Gil A. C. M. et al. Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy //Sao Paulo Medical Journal. – 2007. – Т. 125. – №. 4. – С. 205-209.
  140. Fokunang C. N. et al. Evaluation of hepatotoxicity and nephrotoxicity in HIV patients on highly active anti-retroviral therapy //Journal of AIDS and HIV Research. – 2010. – Т. 2. – №. 3. – С. 046-057.
  141. Pokorska-Śpiewak M. et al. Prevalence and predictors of liver disease in HIV-infected children and adolescents //Scientific Reports. – 2017. – Т. 7. – №. 1. – С. 1-8.
  142. Geffriaud C. et al. Hepatic involvement in HIV 1 virus infection //Gastroenterologie clinique et biologique. – 1988. – Т. 12. – №. 5. – С. 465.
  143. Palchetti, C. Z., Szejnfeld, V. L., de Menezes Succi, R. C., Patin, R. V., Teixeira, P. F., Machado, D. M., & Oliveira, F. L. C. (2015). Impaired bone mineral accrual in prepubertal HIV-infected children: a cohort study. The Brazilian Journal of Infectiou.
  144. Sogni P., Salmon-Céron D., Podevin P. Management of cirrhosis complications in HIV patients coinfected with hepatitis B or C virus //Presse medicale (Paris, France: 1983). – 2005. – Т. 34. – №. 20 Pt 2. – С. 1579.
  145. Sigel K. et al. Cancer screening in patients infected with HIV //Current Hiv/aids Reports. – 2011. – Т. 8. – №. 3. – С. 142-152.
  146. Walenda C. et al. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d’Ivoire, 2000–04 //Journal of tropical pediatrics. – 2009. – Т. 55. – №. 3. – С. 170-176.
  147. Berteloot L. et al. Value of chest x-ray in TB diagnosis in HIV-infected children living in resource-limited countries: the ANRS 12229-PAANTHER 01 study //The International Journal of Tuberculosis and Lung Disease. – 2018. – Т. 22. – №. 8. – С. 844-850.
  148. Rylance S. et al. Effect of antiretroviral therapy on longitudinal lung function trends in older children and adolescents with HIV-infection //PloS one. – 2019. – Т. 14. – №. 3. – С. e0213556.
  149. Norton K. I. et al. Chronic radiographic lung changes in children with vertically transmitted HIV-1 infection //American Journal of Roentgenology. – 2001. – Т. 176. – №. 6. – С. 1553-1558.
  150. Luginbuhl L. M. et al. Cardiac morbidity and related mortality in children with HIV infection //Jama. – 1993. – Т. 269. – №. 22. – С. 2869-2875.
  151. Mantegazza C. et al. Assessment of HIV infection status in children and adolescents through bowel ultrasound //Digestive and Liver Disease. – 2013. – Т. 45. – С. e282-e283.
  152. Unsal A. B. et al. Effect of antiretroviral therapy on bone and renal health in young adults infected with HIV in early life //The Journal of Clinical Endocrinology & Metabolism. – 2017. – Т. 102. – №. 8. – С. 2896-2904.
  153. Zambrano P. O. et al. Renal compromise in HIV/AIDS in patients attended at a chilean children hospital //Revista chilena de infectologia: organo oficial de la Sociedad Chilena de Infectologia. – 2009. – Т. 26. – №. 1. – С. 21-25.
  154. Sigaloff K. C. E. et al. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review //The Lancet infectious diseases. – 2011. – Т. 11. – №. 10. – С. 769-779.
  155. Phillips N. et al. HIV-associated cognitive impairment in perinatally infected children: a meta-analysis //Pediatrics. – 2016. – Т. 138. – №. 5. – С. e20160893.
  156. Фомина М.Ю., Титова М.А. Цереброавскулярные расстройства у детей с перинатальной ВИЧ-инфекцией: клинические и лучевые аспекты.// Журнал инфектологии.-том 10, № 4, 2018.-с.72-77.
  157. Jahanshad N. et al. Brain imaging and neurodevelopment in HIV-uninfected Thai children born to HIV-infected mothers //The Pediatric infectious disease journal. – 2015. – Т. 34. – №. 9. – С. e211.
  158. Dean O. et al. Brain magnetic resonance imaging findings associated with cognitive impairment in children and adolescents with human immunodeficiency virus in Zambia //Pediatric Neurology. – 2020. – Т. 102. – С. 28-35.
  159. Yadava S.K., Guptab R.K., Gargc R.K., Venkateshd V., Guptab P.K., Singhc A.K., Hashema S., Al-Sulaitia A., Kaurae D., Wanga E., Marincolaa F.M., Haris M. Altered structural brain changes and neurocognitive performance in pediatric HIV. NeuroImage: Clinica.
  160. Wade B.S.C., Valcour V.G., Puthanakit T., Saremi A., Gutmanf B.A., Nir T.M., Watson C., Aurpibul L., Pope K., Ounchanum P., Kerr S., Dumrongpisutikul N., Visrutaratna P, Srinakarin J., Pothisri M., Narr K.L., Thompson P.M., Ananworanich, J., Paul R.H., Ja.
  161. Hoare J., Fouche J.-P., Phillips N., Joska J.A., Myer L., Zar H.J., Stein D.J. Structural brain changes in perinatally HIV infected young adolescents in South Africa. Running head: Brain Imaging in adolescents living with HIV. AIDS, Publish Ahead of Print.
  162. Загайнова А.И., Афонина Л.Ю., Воронин Е.Е., Епоян Т.А./Под ред. Загайновой А.И. Книга для настоящих и будущих родителей (информационное пособие для родителей и опекунов детей, затронутых эпидемией ВИЧ-инфекции. – М., 2010. – 187 стр.
  163. Van Elsland S.L., Peters R.P.H., Grobbelaar C., Ketelo P., Kok M.O., Cotton M.F., van Furth A.M. Disclosure of human immunodeficiency virus status to children in South Africa: A comprehensive analysis. S Afr J HIV Med. 2019;20(1), a884.
  164. Kim S.H., Gerver S.M., Fidler S., Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS. 2014;28(13):1945-1956.
  165. Saberi P., Neilands T.B., Vittinghoff E., Johnson M.O., Chesney M., Cohn S.E. Barriers to Antiretroviral Therapy Adherence and Plasma HIV RNA Suppression Among AIDS Clinical Trials Group Study Participants. AIDS Patient Care STDS. 2015 Mar 1; 29(3): 111–1.
  166. Первый Российский консенсус по количественной оценке приверженности к лечению: основные положения, алгоритмы и рекомендации – одобрен XII Национальным конгрессом терапевтов (Москва, 22–24 ноября 2017 г.).//Медицинский вестник Северного Кавказа, 2018, т.13.
  167. Николаев Н.А. Доказательная гипертензиология: пациенториентированная антигипертензивная терапия: монография. ‒ М.: Издательский дом Академии Естествознания, 2015. – 178 с.
  168. Morisky D.E., Green L.W., Levine D.M. Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence. Medical Care. 1986 Jan; Vol. 24, No. 1, pp. 67-74.
  169. Al-Hassany L., Kloosterboer S.M., Dierckx B., Koch B.C. Assessing methods of measuring medication adherence in chronically ill children-a narrative review. Patient Prefer Adherence. 2019;13:1175-1189.
  170. Gopakumar, K.G., Bhat, K.G., Baliga, S., Joseph, N., Mohan, N., & Shetty, A.K. Impact of care at foster homes on the health-related quality of life of HIV-infected children and adolescents: A cross-sectional study from India. Quality of Life Research, 201.
  171. Lyon M.E., Garvie P.A., Briggs L., He, J., Malow R., D’Angelo L.J., McCarter R. Is it safe? Talking to teens with HIV/AIDS about death and dying: A 3-month evaluation of Family Centered Advance Care (FACE) planning – Anxiety, depression, quality of life H.
  172. Xu T., Wu Z., Yan Z., Rou K., Duan S. Measuring health-related quality of life in children living in HIV/AIDS-affected families in rural areas in Yunnan, China: Preliminary reliability and validity of the Chinese version of PedsQL 4.0 Generic Core Scales.
  173. Bomba M., Nacinovich R., Oggiano S., Cassani M., Baushi L., Bertulli C., Longhi D., Coppini S., Parrinello G., Plebani A., Badolato R. Poor health-related quality of life and abnormal psychosocial adjustment in Italian children with perinatal HIV infectio.
  174. Williams P. L. et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection //Pediatrics. – 2006. – Т. 118. – №. 6. – С. e1745-e1757.
  175. Wood S.M., Shah S.S., Steenhoff A.P., Rutstein R.M. The impact of AIDS diagnoses on long- term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV AIDS 2009, 23:1859–1865.
  176. Bucek A., Leu C.-S., Benson S., Warne P., Abrams E.J., Elkington K.S., Dolezal C., Wiznia A., Mellins C.A. Psychiatric Disorders, Antiretroviral Medication Adherence, and Viremia in a Cohort of Perinatally HIV-Infected Adolescents and Young Adults. Pediat.
  177. Lwidiko A., Kibusi S.M., Nyundo A., Mpondo B.C.T. Association between HIV status and depressive symptoms among children and adolescents in the Southern Highlands Zone, Tanzania: A case-control study. PLoS ONE 2018; 13(2): e0193145.
  178. Laughton B., Cornell M., Kidd M., Springer P.E., Dobbels E.F.M.-T., Van Rensburg A.J., Otwombe K., Babiker A., Gibb D.M., Violari A., Kruger M., Cotton M.F. Five year neurodevelopment outcomes of perinatally HIV-infected children on early limited or defer.
  179. Смулевич А.Б. Депрессии в общей медицине. Руководство для врачей. М., Медицинское информационное агентство, 2007 г., - 256 с.
  180. Bjelland I.; Dahl A.A., Haug T., Tangen D., Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. Journal of Psychosomatic Research. 2002; 52 (2): 69–77.
  181. Chan Y.-F., Leung D.Y.P., Fong D.Y.T., Leung C.-M., Lee A.M. Psychometric evaluation of the Hospital Anxiety and Depression Scale in a large community sample of adolescents in Hong Kong. Qual Life Res. 2010; 19:865–873.
  182. Ochigbo S.O., Torty C., Oparah S. Predictors of Anxiety and Depression Among Caregivers of Human Immunodeficiency Virus Positive Children in Calabar, Nigeria. International Journal of HIV/AIDS Prevention, Education and Behavioural Science. 2018; Vol. 4, N.
  183. Savard J., Laberge B., Gauthier J.G., Ivers H., Bergeron M.G. Evaluating anxiety and depression in HIV-infected patients. J Pers Assess. 1998; Dec;71(3):349-67.
  184. Brown L.K., Kennard B.D., Emslie G.J., Mayes T.L., Whiteley L.B., Bethel J., Xu J., Thornton S., Tanney M.R., Hawkins L.A, Garvie P.A., Subramaniam G.A., Worrell C.J., Stoff L.W., and Adolescent Trials Network for HIV/AIDS Interventions. Effective Treatme.
  185. Shaw S, Amico KR. Antiretroviral therapy adherence enhancing interventions for adolescents and young adults 13-24 Years of Age: a review of the evidence base. J Acquir Immune Defic Syndr. 2016;72(4):387-399.
  186. MacPherson P, Munthali C, Ferguson J, et al. Service delivery interventions to improve adolescents’ linkage, retention and adherence to antiretroviral therapy and HIV care. Trop Med Int Health. 2015;20(8):1015-1032.
  187. Casale M, Carlqvist A, Cluver L. Recent interventions to improve retention in HIV Care and adherence to antiretroviral treatment among adolescents and youth: a systematic review. AIDS Patient Care STDS. 2019;33(6):237-252.
  188. Беляева В.В., Афонина Л.Ю., Дмитриева Е.В., Рюмина И.И., Фролов С.А., Шухов В.С., Нилл Макки. Коммуникация и консультирование в области ВИЧ-инфекции. Пособие для медицинских работников. Москва, 2008. – 109 с.
  189. Афонина Л.Ю., Воронин Е.Е. Приверженность антиретровирусной терапии в разрезе био-медицинской сферы. Международная научно-практическая конференция «Актуальные вопросы ВИЧ-инфекции»: Материалы конференции. – СПб: Человек и его здоровье, 2019. – с.16-35.
  190. The European AIDS Clinical Society (EACS) Guidelines Version 10.0 November 2019. 123p. http://www.eacsociety.org.
  191. Епифанов А.Ю. Комплексная оценка и коррекция приверженности ВААРТ. Международная научно-практическая конференция «Актуальные вопросы ВИЧ-инфекции»: Материалы конференции. – СПб: Человек и его здоровье, 2019. – с.83-89.
  192. Biadgilign S. et al. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: A qualitative study //SAHARA-J: Journal of Social Aspects of HIV/AIDS. – 2009. – Т. 6. – №. 4. – С. 148-154.
  193. Shubber Z. et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis //PLoS medicine. – 2016. – Т. 13. – №. 11. – С. e1002183.
  194. Rueda S. et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS //Cochrane database of systematic reviews. – 2006. – №. 3.
  195. Poorolajal J. et al. Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis //Public Health. – 2016. – Т. 139. – С. 3-12.
  196. Cotton M. F. et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial //The Lancet. – 2013. – Т. 382. – №. 9904. – .
  197. Violari A. et al. Early antiretroviral therapy and mortality among HIV-infected infants //New England Journal of Medicine. – 2008. – Т. 359. – №. 21. – С. 2233-2244.
  198. Penazzato M. et al. Optimisation of antiretroviral therapy in HIV‐infected children under 3 years of age //Cochrane Database of Systematic Reviews. – 2014. – №. 5.
  199. Puthanakit T. et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial //The Lancet infectious diseases. – 2012. – Т. 12. – №. 12. – С. 933-941.
  200. Johnson S. et al. Rapid initiation of antiretroviral therapy for people living with HIV //The Cochrane database of systematic reviews. – 2018. – Т. 2018. – №. 2.
  201. Lawn S. D., Török M. E., Wood R. Optimum time to start antiretroviral therapy during HIV- associated opportunistic infections //Current opinion in infectious diseases. – 2011. – Т. 24. – №. 1. – С. 34.
  202. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV- infection. Recommendation for the public health approach. WHO, 2nd edition, Geneva, 2016. 480p. http://www.who.int/hiv.
  203. Foster C., Bamford A., Turkova A., Welch S. and Klein N. On behalf of the PENTA Guidelines Writing Group and PENTA steering committee. Paediatric European Network for Treatment of AIDS. Treatment Guideline 2016 update: antiretroviral therapy recommended f.
  204. Mbuagbaw L. C. E. et al. Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐ naïve individuals //Cochrane Database of Systematic Reviews. –.
  205. Spaulding A., Rutherford G. W., Siegfried N. Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in antiretroviral‐naive individuals //Cochrane Database of Systematic Reviews. – 2010. – №. 8.
  206. Spaulding A., Rutherford G. W., Siegfried N. Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non‐nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in ant.
  207. Penazzato M. et al. Effectiveness of antiretroviral therapy in HIV‐infected children under 2 years of age //Cochrane Database of Systematic Reviews. – 2012. – №. 7.
  208. Kanters S. et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis //The lancet HIV. – 2016. – Т. 3. – №. 11. – С. e510-e520.
  209. Kityo C. et al. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial //PLoS medicine. – 2018. – Т. 15. – №. 12. – С. e1002706.
  210. Fowler M. G. et al. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18- month results of a randomized, double-blind, placebo-controlled trial //.
  211. Barlow-Mosha L. et al. Nevirapine-versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial //Clinical Infectious Diseases. – 2016. – Т. 63. – №. 8. – С. 1.
  212. Денисенко В. Б., Симованьян Э. Н. Совершенствование антиретровирусной терапии у детей с ВИЧ-инфекцией //Детские инфекции. – 2018. – Т. 17. – №. 2.
  213. Cotton M. F. et al. Safety and efficacy of atazanavir powder and ritonavir in HIV-1-infected infants and children from 3 months to< 11 years of age: the PRINCE-2 study //The Pediatric infectious disease journal. – 2018. – Т. 37. – №. 6. – С. e149-e156.
  214. Frange P. et al. Similar efficacy and safety of dolutegravir between age groups of HIV‐1‐ infected paediatric and young adult patients aged 5 years and older //HIV medicine. – 2019. – Т. 20. – №. 8. – С. 561-566.
  215. Paediatric European Network for the Treatment of AIDS (PENTA et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children //Aids. – 2007. – Т. 21. – №. 8. – С. 947-955.
  216. Ciaranello A. L. et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review //Clinical Infectious Diseases. – 2009. – Т. 49. – №. 12. – С. 1915-1927.
  217. Funk M. B. et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children //European journal of medical research. – 2005. – Т. 10. – №. 12. – С. 503.
  218. Ross L. L. et al. Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens //The open AIDS journal. – 2015. – Т. 9. – С. 38.
  219. Hakim J. G. et al. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial //The Lancet Infe.
  220. Национальная ассоциация специалистов в области ВИЧ/СПИДа Клинические рекомендации. ВИЧ-инфекция у детей [Электронный ресурс] // URL: http://rushiv.ru/wp-content/uploads/2019/03/kr459.pdf (Дата последнего обращения: 07.07.2020).
  221. Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single- tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single arm, open-la.
  222. Falcon-Neyra L. et al. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study //Medicine. – 2016. – Т. 95. – №. 24.
  223. Van Dyke R. B. et al. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children //The Journal of infectious diseases. – 2008. – Т. 198. – №. 11. – С. 1599-1608.
  224. Tudor‐Williams G. et al. Etravirine in treatment‐experienced, HIV‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study //HIV medicine. – 2014. – Т. 15. – №. 9. – С. 513-524.
  225. Rutherford G. W. et al. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure //Aids. – 2014. – Т. 28. .
  226. Davies M. A. et al. The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure //Tropical Medicine & International Health. – 2012. – Т. 17. – №. 11. – С. 1386-1390.
  227. Grennan J.T., Loutfy M.R., Su D., et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205(8):1230-1238.
  228. Vandenhende M.A., Perrier A., Bonnet F., et al. Risk of virological failure in HIV-1-infected patients experiencing lowlevel viraemia under active antiretroviral therapy (ANRS C03 cohort study). Antivir Ther. 2015;20(6):655-60.
  229. Ribaudo H.J., Lennox J., Currier J., et al. Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold <200 copies/mL better than <50 copies/mL? an analysis of ACTG Studies. Abstract 580. Presented at: Conference on Retroviruse.
  230. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection (Last Updated: April 14, 2020; Last Reviewed: April 14, 2020) [Электронный ресурс] // URL: https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv/0 (Дата последнего обращения 08.
  231. Collins I. J. et al. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration //The Lancet HIV. – 2019. – Т. 6. – №. 2. – С. e105-e115.
  232. Goetghebuer T. et al. Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand //Clinical Infectious Diseases. – 2018.
  233. Govender R. et al. Neurologic and neurobehavioral sequelae in children with human immunodeficiency virus (HIV-1) infection //Journal of child neurology. – 2011. – Т. 26. – №. 11. – С. 1355-1364.
  234. Bacha T., Tilahun B., Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy //BMC infectious diseases. – 2012. – Т. 12. – №. 1. – С. 197.
  235. Westley B. P. et al. Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children //Clinical Infectious Diseases. – 2012. – Т. 55.
  236. Mullen J. et al. Antiretroviral drug resistance among HIV‐1 infected children failing treatment //Journal of medical virology. – 2002. – Т. 68. – №. 3. – С. 299-304.
  237. Agwu A. L., Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV‐infected adolescents //Journal of the International AIDS Society. – 2013. – Т. 16. – №. 1. – С. 18579.
  238. Obasa A. E. et al. Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa //Frontiers in Microbiology. – 2020. – Т. 11. – С. 438.
  239. Patten G. et al. What should we do when HIV-positive children fail first-line combination antiretroviral therapy? a comparison of 4 ART management strategies //The Pediatric infectious disease journal. – 2019. – Т. 38. – №. 4. – С. 400.
  240. Ramos J.T., De Jose M.I., Duenas J., et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr Infect Dis J. 2005;24(10):
  241. Resino S., Bellon J.M., Munoz-Fernandez M.A., Spanish Group of HIV Infection. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV- infected children with severe-moderate immunodeficiency. J Antimicrob Chemother. .
  242. Violari A., Bologna R., Kumarasamy N., et al. Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial. Pediatr Infect Dis J. 2015;34(5):e132-137.
  243. Blanche S., Bologna R., Cahn P., et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment experienced children and adolescents. AIDS. 2009;23(15):2005- 2013.
  244. Viani R.M., Alvero C., Fenton T., et al. Safety, Pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. Pediatr Infect Dis J. 2015;34(11):1207-13.
  245. Zheng Y., Hughes M.D., Lockman S., et al. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014;59(6):888-896.
  246. Harrison L., Melvin A., Fiscus S., et al. HIV-1 drug resistance and second-line treatment in children randomized to switch at low versus higher RNA thresholds. J Acquir Immune Defic Syndr. 2015;70(1):42-53.
  247. Meyers T., Sawry S., Wong J.Y., et al. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa. Pediatr Infect Dis J. 2015;34(2):175-179.
  248. Galan I., Jimenez J.L., Gonzalez-Rivera M., et al. Virological phenotype switches under salvage therapy with Lopinavir/ritonavir in heavily pretreated HIV-1 vertically infected children. AIDS. 2004;18(2):247-255.
  249. Frange P., Chaix M. L., Blanche S. Preserving future therapeutic options: should we limit the lamivudine use in young HIV-1 infected children initiating first-line HAART? //Aids. – 2013. – Т. 27. – №. 2. – С. 151-154.
  250. Lu X. et al. HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China //AIDS research and therapy. – 2017. – Т. 14. – №. 1. – С. 4.
  251. Zhong M. et al. Analysis of HIV genotypic drug resistance among pediatric HIV/AIDS cases with virological failure after free antiretroviral therapy in Yunnan province //Zhonghua yi xue za zhi. – 2014. – Т. 94. – №. 12. – С. 884-888.
  252. McNamara, J. (2005). Clinical trials for HIV-infected children. In S. Zeichner & J. Read (Eds.), Textbook of Pediatric HIV Care (pp. 635-642). Cambridge: Cambridge University Press. doi:10.1017/CBO9780511544798.046.
  253. World Health Organization et al. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision. – World Health Organization, 2010.
  254. Rojas Sánchez P., Holguín A. Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review //Journal of Antimicrobial Chemotherapy. – 2014. – Т. 69. – №. 8. – С. 2032-2042.
  255. Patel K. et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents //AIDS (London, England). – 2009. – Т. 23. – №. 14. – С. 1893.
  256. Van den Hof M. et al. CNS penetration of ART in HIV-infected children //Journal of Antimicrobial Chemotherapy. – 2018. – Т. 73. – №. 2. – С. 484-489.
  257. Kanters S. et al. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis //The lancet HIV. – 2017. – Т. 4. – №. 1. – С. e31-e40.
  258. Clay P. G. The abacavir hypersensitivity reaction: a review. – 2002.
  259. Федеральный закон от 30 марта 1995 г. № 38-ФЗ «О предупреждении распространения в Российской Федерации заболевания, вызываемого вирусом иммунодефицита человека (ВИЧ-инфекции)».
  260. Распоряжение Правительства Российской Федерации от 20 октября 2016г № 2203-р «Об утверждении Государственной стратегии противодействия распространению ВИЧ- инфекции в Российской Федерации на период до 2020 года и дальнейшую перспективу».
  261. Федеральный закон от 21 ноября 2011 г. N 323-ФЗ “Об основах охраны здоровья граждан в Российской Федерации”, Федеральный закон от 29.11.2010 № 326-ФЗ “Об обязательном медицинском страховании в Российской Федерации.”
  262. Suksomboon N., Poolsup N., Ket‐Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother‐to‐child transmission of HIV infection //Journal of clinical pharmacy and therapeutics. – 2007. – Т. 32. – №. 3. – С. 293-3.
  263. Siegfried N. et al. Antiretrovirals for reducing the risk of mother‐to‐child transmission of HIV infection //Cochrane database of systematic reviews. – 2011. – №. 7.
  264. Адамян Л.В., Афонина Л.Ю., Баранов И.И., Воронин Е.Е., Кан Н.Е., Кузьмин В.Н., Козырина Н.В., Покровский В.В., Садовникова В.Н., Тютюнник В.Л., Юрин О.Г. Применение антиретровирусных препаратов в комплексе мер, направленных на профилактику передачи ВИЧ от.
  265. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Transmission in the United States, 2019.
  266. Katz I.T., Shapiro D.E., Tuomala R. Factors associated with lack of viral suppression at delivery. Ann Intern Med. 2015;162(12):874-875.
  267. RitchieLMP. What interventions are effective in improving uptake and retention of HIV- positive pregnant and breastfeeding women and their infants in prevention of mother to child transmission care programmes in low-income and middle-income countries // BMJ open. – 2019. – Т. 9. – №. 7. – С. e024907.
  268. Horvath T. et al. Interventions for preventing late postnatal mother‐to‐child transmission of HIV //Cochrane database of systematic reviews. – 2009. – №. 1.
  269. Chiappini E. et al. Use of combination neonatal prophylaxis for the prevention of mother-to- child transmission of HIV infection in European high-risk infants //Aids. – 2013. – Т. 27. – №. 6. – С. 991-1000.
  270. Kovalchik S. A. Mother’s CD4+ count moderates the risk associated with higher parity for late postnatal HIV-free survival of breastfed children: an individual patient data meta-analysis of randomized controlled trials //AIDS and Behavior. – 2012. – Т. 16.
  271. Kassa G. M. Mother-to-child transmission of HIV infection and its associated factors in Ethiopia: a systematic review and meta-analysis //BMC infectious diseases. – 2018. – Т. 18. – №. 1. – С. 1-.
  272. Dunn D. HIV Paediatric Prognostic Markers Collaborative Study Group Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis //Lancet. – 2003. – Т. 362. – №. 9396. – С.
  273. Chiappini E. et al. for the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk inf.
  274. John G. C. et al. Timing of breast milk HIV-1 transmission: a meta analysis //East African medical journal. – 2001. – Т. 78. – №. 2. – С. 75-79.
  275. Yah C. S., Tambo E. Why is mother to child transmission (MTCT) of HIV a continual threat to new-borns in sub-Saharan Africa (SSA) //Journal of Infection and Public Health. – 2019. – Т. 12. – №. 2. – С. 213-223.
  276. Victoria C. G. et al. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis //Lancet (British edition). – 2000. – Т. 355. – №. 9202. – С. 451-455.
  277. Daniels B. et al. Effect of co-trimoxazole prophylaxis on morbidity and mortality of HIV- exposed, HIV-uninfected infants in South Africa: a randomised controlled, non-inferiority trial //The Lancet Global Health. – 2019. – Т. 7. – №. 12. – С. e1717-e1727.
  278. Zachariah R. et al. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries //The Lancet Infectious Diseases. – 2007. – Т. 7. – №. 10. – С. 686-693.
  279. Boettiger D. C. et al. Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality Rates in Children Without Severe Immunodeficiency //Journal of the Pediatric Infectious Diseases Society. –.
  280. MR B.-L., Drouin O., Bartlett G., et al. Incidence and prevalence of opportunistic and other infections and the impact of antiretroviral therapy among HIV-infected children in low- and middle-income countries: a systematic review and metaanalysis. Clin In.
  281. World Health Organization et al. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. – World Health Organization, 2016.
  282. Ford, N., Shubber, Z., Calmy, A., Irvine, C., Rapparini, C., Ajose, O., … Mayer, K. H. (2015). Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review. Clinical Infectious Diseases, 60(suppl 3), S170–S17.
  283. McManus H., Hoy J.F., Woolley I., Boyd M.A., Kelly M.D., Mulhall B., Roth N.J., Petoumenos K., Law M.G. and the Australian HIV observational database. Recent trends in early stage response to combination antiretroviral therapy in Australia. Antivir Ther. .
  284. «90-90-90» Амбициозная цель в области лечения, способствующая прекращению эпидемии СПИДа. Объединенная программа Организации Объединенных Наций по ВИЧ/ СПИДу (ЮНЭЙДС): Женева, Швейцария, 2014.
  285. Global Health Sector Strategy on HIV 2016–2021 Towards Ending AIDS. WHO, Geneva: 2016.
  286. Patel A., Hirschhorn L., Fullem A., Ojikutu B., Oser R. Adult Aherence to Treatment and Retention in Care. Arlington, VA: USAID | AIDSTAR-ONE PROJECT, Task Order 1, June 2010.
  287. Lamb M. R., Fayorsey R., Nuwagaba-Biribonwoha H., Viola V., Mutabazi V., Alwar T., Casalini C., Elul B. High attrition before and after ART initiation among youth (15–24 years of age) enrolled in HIV care. AIDS. 2014 February 20; 28(4): 559–568.
  288. WHO. 2003. Adherence to Long-term Therapies: Evidence for Action. Geneva:
  289. Shubber Z., Mills E.J., Nachega J.B., Vreeman R., Freitas M., Bock P., et al. (2016) Patient- Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med 13(11).
  290. Nachega J.B., Parienti J.J., Uthman O.A., et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. May 2014;58(9):1297-1307.
  291. Langebeek N., Gisolf E. H., Reiss P. Vervoort S. C., Hafsteinsdóttir T. B., Richter C., Sprangers M. AG., Nieuwkerket P. T. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC .
  292. A. Antinori, Arendt, J.T. Becker, B.J. Brew, D.A. Byrd, PhD, M. Cherner, PhD, D.B. Clifford, P. Cinque, L.G. Epstein, K. Goodkin, M. Gisslen, I. Grant, R.K. Heaton, J. Joseph, K. Marder, C.M. Marra, J.C. McArthur, M. Nunn, R.W. Price, L. Pulliam, K.R. Rob.
  293. Gandhi N.D., Moxley R.T., Creighton J., Roosa H.V., Skolasky R.L., Selnes O.A., McArthur J., Sacktor N. Comparison of scales to evaluate the progression of HIVassociated neurocognitive disorder. HIV Ther. 2010 May ; 4(3): 371–379.
  294. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS). July 14, 2016. http://www.
  295. Федеральный закон "О внесении изменений в Федеральный закон "Об основах охраны здоровья граждан в Российской Федерации" по вопросам оказания паллиативной медицинской помощи" от 06.03.2019 № 18-ФЗ.
  296. Приказ Минздрава России № 345н, Минтруда России от 31.05.2019 № 372н «Об утверждении положения об организации оказания паллиативной медицинской помощи, включая порядок взаимодействия медицинских организаций, организаций социального обслуживания и общественных объединений, иных некоммерческих организаций, осуществляющих свою деятельность в сфере охраны здоровья».
  297. Приказ Минздрава России № 348н от 31 мая 2019 года «Об утверждении перечня медицинских изделий, предназначенных для поддержания органов и систем организма человека, предоставляемых для использования на дому».
  298. Приказ Минздрава России № 505н от 10 июля 2019 года «Об утверждении Порядка передачи от медицинской организации пациенту (его законному представителю) медицинских изделий, предназначенных для поддержания функций органов и систем организма человека, для использования на дому при оказании паллиативной медицинской помощи».
  299. Приказ МЗ РФ № 831 от 3 октября 2019 года «Об утверждении ведомственной целевой программы «Развитие системы оказания паллиативной медицинской помощи»

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*